Clinical Trials Browser

Phase 2 × Atorvastatin × 90 days × Clear all

NCT04915183 2026-03-09

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Phase 2 Recruiting

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

NCT04767984 2026-01-21

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Phase 2 Active not recruiting

Gastrointestinal

Colitis, Ulcerative, Colorectal Neoplasms